Atrion (NASDAQ:ATRI) Shares Gap Up to $437.08

Shares of Atrion Co. (NASDAQ:ATRIGet Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $437.08, but opened at $450.00. Atrion shares last traded at $450.00, with a volume of 7,512 shares traded.

Wall Street Analysts Forecast Growth

Separately, upgraded shares of Atrion from a “sell” rating to a “hold” rating in a research report on Friday, March 1st.

Get Our Latest Stock Report on Atrion

Atrion Stock Performance

The firm’s 50-day moving average is $378.56 and its two-hundred day moving average is $367.82. The stock has a market cap of $815.85 million, a P/E ratio of 42.03 and a beta of 0.58.

Atrion (NASDAQ:ATRIGet Free Report) last posted its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The firm had revenue of $43.58 million during the quarter.

Atrion Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 15th will be given a dividend of $2.20 per share. This represents a $8.80 annualized dividend and a dividend yield of 1.90%. The ex-dividend date is Thursday, March 14th. Atrion’s payout ratio is 79.78%.

Institutional Trading of Atrion

Institutional investors and hedge funds have recently made changes to their positions in the business. Copeland Capital Management LLC lifted its stake in Atrion by 56.4% in the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 31 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in Atrion during the fourth quarter worth approximately $36,000. FMR LLC lifted its position in Atrion by 38.0% during the first quarter. FMR LLC now owns 69 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 19 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in Atrion during the third quarter worth approximately $60,000. Finally, Advisor Group Holdings Inc. acquired a new stake in Atrion during the fourth quarter worth approximately $65,000. Institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

(Get Free Report)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Articles

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with's FREE daily email newsletter.